US Pharma MarketingEMA validates Pfizer and Valneva’s Lyme disease vaccine
EMA validates Pfizer and Valneva’s Lyme disease vaccine is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The EMA has validated the MAA from Pfizer and Valneva for their Lyme disease vaccine candidate, PF-07307405.
Source: Pharmaceutical Technology